| I NT ROD U CTI ON
Attempted prediction of antimicrobial drug efficacy in clinical infections requires knowledge of pharmacokinetic data indicative of drug concentration at the infected site, and pharmacodynamic data describing the association between drug exposure and bacterial killing. 1, 2 The minimum inhibitory concentration (MIC) of an Gentamicin is an aminoglycoside antimicrobial commonly used in horses at a dosage of 6.6 mg/kg IV once daily. 3, 4 The drug exhibits concentration-dependent bacterial killing which is best predicted by the ratio of maximum plasma concentration of gentamicin (C max ) to the MIC of gentamicin for the bacteria being targeted. It has been suggested that a C max : MIC ratio of between 8 and 10 is required for effective aminoglycoside therapy. [5] [6] [7] Therapeutic monitoring of plasma concentrations of gentamicin in equine clinical practice has become more routine in larger hospitals, allowing more informed and safe selection of drug and dosage regimens. However, in the light of such data, concern has been raised that standard dosing of 6.6 mg/kg gentamicin IV q24h often might not attain plasma concentrations adequate for effective treatment of infections in equine patients. 8 The current study aimed to examine plasma gentamicin concentrations in a larger population of equine clinical patients than has been examined in previous studies and, furthermore, to determine the typical MIC results obtained from pathogens affecting horses to enable more informed assessment of the predicted efficacy of a dosage of 6.6 mg/ kg gentamicin IV.
| M E TH ODS

| Therapeutic monitoring of gentamicin
Clinical records of in-patients at The Liphook Equine Hospital were searched between July 2012 and July 2015 for data related to therapeutic monitoring of gentamicin. Cases were selected where both a peak and subsequent trough sample were collected from the same horse after the first dose of 6.6 mg/kg gentamicin sulfate IV, calculated from body mass as measured on a calibrated weighbridge. Horses <1 year of age were excluded. Peak concentrations were measured at 1 hour (C 60min ) and trough concentrations were measured at 24 hours (C 24h ) after dosing. Free plasma gentamicin was measured using an enzyme immunoassay method (Cedia Gentamicin II, Microgenics, Fremont, California), determined using a Prestige 24i analyser (Tokyo Boeki, Tokyo, Japan). The assay was validated previously yielding intraassay and inter-assay variability <9% and measured recovery of 106%-112% of spiked gentamicin. The lower limit of detection for the assay is 0.24 lg/mL gentamicin.
| Antimicrobial susceptibility testing
Records at The Liphook Equine Hospital Laboratory were searched for submitted bacteriologic samples for which the MIC of gentamicin was measured in aerobic gram-negative bacilli and Staphylococcus sp.
between October 2014 and July 2015. Although some of the bacteriologic data came from the same horses sampled for serum gentamicin concentrations, not all horses were sampled for both serum and bacteriologic data, and many bacteriologic samples were obtained from horses where serum samples were not taken or included in the study.
Additionally, samples obtained from hospitalized horses were considered separately from samples collected in ambulatory practice.
Samples typically were first plated onto Columbia blood agar and and C 24h were, respectively, 21.4 lg/mL (range, 4.4-42.6 lg/mL) and 0.2 lg/mL (range, 0-5.7 lg/mL). The distribution of plasma concentra-
tions among the population of tested horses is detailed in Figure 1A ,B.
The likelihood of attaining adequate serum gentamicin concentrations to kill bacteria falling into the various MIC categories (0.5 to 16 mg/mL) was calculated based on an estimated target C 60min of [8] [9] [10] times the MIC (Table 1) . Almost all treated horses attained serum gentamicin concentrations expected to be efficacious against bacteria with MIC 1 lg/mL and most horses (between 60.6 and 82.2%) attained serum gentamicin concentrations expected to be efficacious against 4 lg/mL, and none attained gentamicin concentrations predictive of efficacy versus bacteria with MIC 8 lg/mL. The C 24h was >1 lg/mL in 40/348 (11.5%) horses and >2 lg/mL in 9/348 (2.6%) horses.
A total of 536 gram-negative and Staphylococcal bacterial isolates was identified and had MIC results determined. Distribution of bacteria among groups and anatomic sites of origin are described in Table 2 . Of the 536
isolates, 503 (94%) were submitted from ambulatory practices across the United Kingdom and the remaining 33 (6%) from in-patients at The Liphook Equine Hospital. Isolates from these 2 groups were separated before determining the MIC distributions of both data sets ( Table 3) .
Comparison of MIC results derived from ambulatory and hospital isolates indicated significantly higher MIC results for hospital isolates of Enterobacteriaceae (P 5 .001) and Staphylococci (P < .001), but not for "other gram-negative bacilli" (P 5 .79). No hospital Pseudomonas isolates were available for comparison.
| D ISC USSION
Our study found that horses treated with gentamicin sulfate at a dosage of 6.6 mg/kg IV q24h attained a median C 60min of 21.4 lg/mL, with 335/339 (98.8%) samples reaching a C 60min of 10 lg/mL ( Figure 1A ) and 330/339 (97.3%) samples having a C 24h of 2 lg/mL ( Figure 1B ), corresponding to recommendations for therapeutic gentamicin monitoring in horses. 9 After examination of bacterial isolates from clinical equine patients, the gentamicin MIC results were significantly higher for hospital-derived isolates of Enterobacteriaceae and
Staphylococci as compared to those obtained from ambulatory practice, implying greater resistance to gentamicin in samples from the hospital sources. In both populations, however, the MIC distribution was approximately bimodal with most isolates being unequivocally susceptible or resistant ( Table 3 ). The CLSI is the only organization thus far to have produced recommendations for veterinary species (Table 4) . The CLSI breakpoint recommendations for humans frequently are higher than those of EUCAST, with a greater likelihood of bacteria being judged susceptible using CLSI than EUCAST recommendations. 10, 11 Breakpoints are derived from multiple data sources and considerations including pharmacokinetic data and how the drug is used in clinical practice, typical bacterial MIC distributions and resistance mechanisms, predictive computer algorithms, and feedback from clinical outcomes. 1,2,12,13 Unfortunately equine-specific recommendations are quite sparse, leading to inter-species assumptions that might prove to be inappropriate given different clinical and pharmacokinetic factors. In fact, even the equinespecific gentamicin data produced by the CLSI 10 refers to IM dosing with 6.6 mg/kg, which might differ slightly compared with the standard IV dosing used in horses. Inevitably, setting of these breakpoints is work in progress in equine medicine.
A key and fundamental principle of setting MIC breakpoints is that they correspond to realistically achievable antimicrobial concentrations at the site of infection, using standard dosages in vivo. 14 and 82%) reached a C 60min predictive of efficacy versus bacteria with MIC of 2 lg/mL (C 60min >16-20 lg/mL). Because fewer than 3.4% of serum samples had gentamicin concentrations thought adequate to kill bacteria with MIC of 4 lg/mL (C 60min >32-40 lg/mL), it seems unlikely that a dosage of 6.6 mg/kg gentamicin IV would be efficacious against such isolates unless the infection was at a site of known gentamicin accumulation such as the urinary tract. 15 Given the plasma concentrations of gentamicin typically seen in our study and a target C 60min of 8 to 10 times the MIC of gentamicin for the bacteria concerned, it is difficult to justify MIC breakpoint recommendations > 2 lg/mL, at least in this population of horses. This conclusion is consistent with CLSI equine-specific recommendations indicating that for Enterobacteriaceae, Pseudomonas aeruginosa, and Actinobacillus pleuropneumoniae, lg/mL immediately post-dosing and 41.6 lg/mL 30 minutes after 6.6 mg/kg IV. 3, 16 A postoperative study of colic cases found the mean plasma gentamicin concentration to be 40.7 lg/mL 20 minutes after 6.6 mg/kg IV gentamicin, 4 and a more recent study of hospitalized horses indicated a mean plasma gentamicin concentration of 26.7 lg/ mL at 30 minutes, using a median dosage of 6.7 mg/kg gentamicin IV, with 17% of peak concentrations >32 lg/mL. 8 However, the different studies are not readily comparable given possible methodologic differences (eg, measurement of free or total drug) and, most importantly, differences in timing of sampling and state of health of the tested subjects. Clearly, peak plasma concentration is a time-dependent variable and different times of sampling will have a large and unpredictable effect on measured plasma concentrations. 17 The most appropriate time for determining the relevant plasma concentration for clinical therapeutic monitoring of horses has not been established. It is suggested to be between 30 and 60 minutes to allow adequate time for tissue distribution of drug, but not allowing too much time for substantial drug elimination. 9 In any case, it is likely that the most appropriate collection time would vary among different sites of infection, adding to the uncertainty about the best time interval. It is also evident that sick horses treated with gentamicin may demonstrate different pharmacokinetics, making it additionally difficult to extrapolate from studies of healthy experimental horses to those with clinical disease. 8, 18 Unfortunately, in most clinical infections, no data are available on actual infection site drug concentrations, especially in diseased horses. Intuitively, these concentrations will be highly variable depending on the actual site and severity of systemic illness. Therefore, using peak plasma concentration at a given time point is always a compromise and most likely often inaccurately reflects actual peak concentration at the infection site. Thus, given these variables for measuring a clinically meaningful peak plasma concentration, the current study and a previous study 8 probably offer the most useful approximations and had similar findings, given the earlier sampling time of 30 minutes in the previous study. 8 Neither study supported the use of gentamicin at a dosage of 6.6 mg/ kg IV for the treatment of infections caused by bacteria with MIC 4 lg/mL, and it seems inconceivable that success could be obtained against bacteria with MIC 8 lg/mL. This conclusion concurs with CLSI recommendations that bacteria with MIC 8 lg/mL should be regarded as resistant and that those with MIC 4 lg/mL as having intermediate sensitivity suggesting therapeutic success might only be possible using higher dosages or when infection is at sites of drug accumulation (eg, urine). The previous study 8 further investigated the effect of higher dosages of gentamicin between 7.7 and 15.0 mg/kg and found that although these were significantly more likely to attain C 30min >32 lg/mL (possibly adequate to kill bacteria with MIC of 4 lg/ mL), they still failed to do so in the majority of cases.
It is also relevant that the current study, along with others, 19, 20 found an essentially bimodal distribution of MICs in clinical isolates.
Most isolates from both ambulatory and hospital samples in the current study had MICs that were either 2 lg/mL (susceptible) or 8 lg/mL (resistant), with only 9/536 (1.7%) isolates having an intermediate MIC of 4 lg/mL (Table 3) . Overall, this finding suggests a very low likelihood of clinical benefit from increased dosages of gentamicin in the horses in our study, and that an alternative antimicrobial may be a better solution than an increased dosage in order to decrease the likelihood of sub-therapeutic high-dose gentamicin treatment with its implications for treatment failure, bacterial resistance, and toxicity.
Aminoglycoside-associated nephrotoxicity has been associated with multiple-daily versus once-daily dosing regimens and is proposed to be related to trough plasma drug concentrations, although it has been suggested that increased trough concentrations could be a result rather than a cause of renal dysfunction. 21, 22 Interestingly, there is little mention of ototoxicity in horses, which may be a major complication in human patients. 23 Recommended target trough concentrations are variable although generally considered to be no higher than 1-2 lg/ mL, although little evidence supports this concentration range. 9 In the present study, and in another recent report, 8 C 24h concentrations were rarely of concern, being >2 lg/mL in only 2.6% of cases, although more work needs to be done. reported previously. 24 Increased resistance in bacteria derived from hospitalized populations has been reported previously 25 and also was clearly evident in the current study. Approximately 90% of isolates from ambulatory practices appeared susceptible to gentamicin (MIC 2 lg/mL) in contrast to approximately 40% of isolates from the hospital.
Given that IV administration of antimicrobials is inconvenient in ambulatory practice, the hospital-derived bacteriology data (Table   3 , Liphook Equine Hospital) may be more clinically relevant, and also more consistent with previous studies of bacterial gentamicin susceptibilities. 19, 20, 26, 27 However, the different resistance patterns may act as pathogens. 28 Additionally, given the retrospective nature of our clinical study, it proved difficult to determine with reasonable certainty that any isolates could be conclusively dismissed as contaminants.
All horses treated with gentamicin in the current study were weighed accurately, giving reasonable reassurance that dosing was consistent and precise. Indeed, in most cases, the drug was administered via an IV catheter, offering assurance of effective and complete administration. Although a few horses were treated via IV injection without a catheter, injection was always performed by experienced equine clinicians. Still, it remains possible that occasional partial perivascular injection or leakage could explain some low C 60min concentrations. Similarly, the laboratory analysis of plasma samples was performed as part of standard clinical care and duplicate samples were neither tested nor stored as might be done in an experimental study. Thus, occasional laboratory error cannot be ruled out, but is expected to be very rare. Anecdotally, on occasion an unexpectedly low C 60min result was reanalyzed, but the findings always concurred with the original result.
Thus, the present study found that very few horses receiving 6.6 mg/kg IV q24h attained C 60min results considered adequate to kill bacteria with MIC 4 lg/mL as has been found previously. 8 Bacterial MIC 2 lg/mL are very common in infections of horses sampled in ambulatory practice and would be expected to respond well to standard gentamicin dosages. However, isolates sensitive to standard gentamicin dosages were significantly less common in hospitalized horses. Given the relatively limited increases in C 60min observed in response to dosage increases 8 and the rarity of isolates with intermediate MIC, there seems to be little justification for increasing the standard dosage of gentamicin from 6.6 mg.kg IV q24h, at least in this population of horses.
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